Gara Jalqabaatti › Kansaar Onnee Triple-Negative › Illinois › Chicago
Qorannoo klinikaalii Kansaar Onnee Triple-Negative Chicago, IL keessatti
Qorannoo 16 Kansaar Onnee Triple-Negative f Chicago fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Chicago Hospital, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Namoota walitti qabaa jiraSadarkaa 3
- University of Illinois Cancer Center ( Site 0044), Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Northwestern University Feinberg School of Medicine, Chicago
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Namoota walitti qabaa jiraSadarkaa 3
- Northwestern Medicine, Chicago
- Rush University Medical Center, Chicago
- University of Chicago Medical Center, Chicago
SMP-3124LP in Adults With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Namoota walitti qabaa jiraSadarkaa 2/3
- Local Institution - 0280, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Northwestern University, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1
- The University of Chicago Medical Center (UCMC), Chicago
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Namoota walitti qabaa jiraSadarkaa 1
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
Study of XB010 in Subjects With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Chicago Medical Center, Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Namoota walitti qabaa jiraSadarkaa 1/2
- Northwestern Memorial Hospital, Chicago
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of Chicago, Chicago
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Namoota walitti qabaa jiraSadarkaa 2
- University of Chicago Medical Center, Chicago
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Namoota walitti qabaa jiraSadarkaa 1
- UChicago Medicine Comprehensive Cancer Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- University of Chicago, Chicago
Qorannoo Kansaar Onnee Triple-Negative magaalota biroo keessatti
- Houston, TXQorannoo 42
- New York City, NYQorannoo 31
- Nashville, TNQorannoo 28
- Los Angeles, CAQorannoo 27
- Boston, MAQorannoo 26
- San Antonio, TXQorannoo 23
- St. Louis, MOQorannoo 21
- Arlington, VAQorannoo 20
- Atlanta, GAQorannoo 20
- Dallas, TXQorannoo 18
- Columbus, OHQorannoo 16
- Grand Rapids, MIQorannoo 15
Qorannoo biroo Chicago keessatti
- Kansara Qara'a Non-Small CellQorannoo 61
- Saree OljooQorannoo 59
- Saree (Gosoota Hunda)Qorannoo 51
- Kansara MetastatikiiQorannoo 45
- Kansarii ProstateQorannoo 45
- Dhibee QaraQorannoo 41
- ObesityQorannoo 41
- Kansarii OvariiQorannoo 36
- Kansarii ColorectalQorannoo 34
- StrokeQorannoo 34
- Cufama OnneeQorannoo 31
- Baayyee UlfaataaQorannoo 29
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.